Board meetings, strategic plans, and buyer signals from David Flanagan’s organization
May 21, 2026·BoardMeeting
Board
Ibc Meeting Minutes
The committee discussed several research protocols, including renewals and amendments involving molecular pathways in Frontotemporal dementia, virus-mediated gene transfer for cardiac arrhythmia treatment, circadian rhythm studies in Drosophila, HIV research, Hedgehog signaling pathways in organogenesis and tumorigenesis, ocular therapy pharmacology, antibody diversity mechanisms, skeletal homeostasis, and oligonucleotide therapeutics development. Additionally, the committee reviewed recent incidents regarding employee health services and received updates on ongoing studies.
Enterprise
Get verified public-sector contacts at scale
Find verified emails, direct dials, role context, job-change updates, and organization signals across every public-sector account you sell to.
The Institutional Biosafety Committee reviewed and discussed several research protocols, including renewals and amendments regarding microbial modulation, RNA-based therapeutics, and host-pathogen interactions. Key topics included the use of various viral vectors, CRISPR-mediated gene editing in different cell lines and animal models, and safety protocols for BSL-2 and BSL-3 facilities. The committee also addressed information regarding the movement of large animals between research facilities and received updates on clinical study protocols for immunotherapies and pneumococcal pneumonia research.
Mar 19, 2026·BoardMeeting
Board
Institutional Biosafety Committee Meeting Minutes
The committee reviewed reports on incidents involving EHS, including needlesticks and bites, and discussed the status of various open accidents. Several research protocols were reviewed, discussed, and voted on, covering topics such as gene silencing therapeutics for ALS-FUS, SARS-CoV-2 biocontainment level adjustments, gut microbiome research, axonal injury in mice, translational epigenetics using genomic editing, and fetal cell isolation methods. Additionally, the meeting included updates on BSL-3 and ABSL-3 facility improvements, information on chemical safety, a discussion on biohazard waste disposal, and updates on ongoing clinical trial protocols.
Feb 12, 2026·BoardMeeting
Board
Institutional Biosafety Committee Meeting Minutes
The committee reviewed reports on incidents and accidents from Employee Health Services, including both past and recent BSL-3 laboratory exposures and animal-related incidents. Eleven research protocols were discussed, covering studies on RNA structure, CAR T-cell therapy for systemic lupus erythematosus, metabolic disease, stress response signaling pathways, T cell activation, innate immune responses, translational control, immune responses to pathogens and cancers, and protein/antibody generation. Most protocols were approved pending completion of specified action items regarding experimental methodology and biosafety clarifications. Additionally, the meeting addressed BSL-3 and ABSL-3 facility status and safety design plans.
Extracted from official board minutes, strategic plans, and video transcripts.
